Adalimumab linked to lower risk of Crohn's recurrence

11/24/2013 | Healio (free registration)

Crohn's disease patients taking adalimumab following intestinal resection had a lower risk of disease recurrence, compared with those taking the traditional drugs azathioprine and mesalamine, Italian researchers report in The American Journal of Gastroenterology. Data also showed patients taking adalimumab had higher quality of life scores.

View Full Article in:

Healio (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY